151 related articles for article (PubMed ID: 27105209)
1. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Zivadinov R; Jakimovski D; Gandhi S; Ahmed R; Dwyer MG; Horakova D; Weinstock-Guttman B; Benedict RR; Vaneckova M; Barnett M; Bergsland N
Expert Rev Neurother; 2016 Jul; 16(7):777-93. PubMed ID: 27105209
[TBL] [Abstract][Full Text] [Related]
2. Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
Rocca MA; Romanò F; Tedone N; Filippi M
J Neurol; 2024 May; ():. PubMed ID: 38691168
[TBL] [Abstract][Full Text] [Related]
3. Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.
Lysandropoulos AP; Absil J; Metens T; Mavroudakis N; Guisset F; Van Vlierberghe E; Smeets D; David P; Maertens A; Van Hecke W
Brain Behav; 2016 Feb; 6(2):e00422. PubMed ID: 27110445
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
5. Brain health: time matters in multiple sclerosis.
Giovannoni G; Butzkueven H; Dhib-Jalbut S; Hobart J; Kobelt G; Pepper G; Sormani MP; Thalheim C; Traboulsee A; Vollmer T
Mult Scler Relat Disord; 2016 Sep; 9 Suppl 1():S5-S48. PubMed ID: 27640924
[TBL] [Abstract][Full Text] [Related]
6. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
[TBL] [Abstract][Full Text] [Related]
7. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
8. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
[TBL] [Abstract][Full Text] [Related]
9. Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Jokubaitis VG; Spelman T; Kalincik T; Lorscheider J; Havrdova E; Horakova D; Duquette P; Girard M; Prat A; Izquierdo G; Grammond P; Van Pesch V; Pucci E; Grand'Maison F; Hupperts R; Granella F; Sola P; Bergamaschi R; Iuliano G; Spitaleri D; Boz C; Hodgkinson S; Olascoaga J; Verheul F; McCombe P; Petersen T; Rozsa C; Lechner-Scott J; Saladino ML; Farina D; Iaffaldano P; Paolicelli D; Butzkueven H; Lugaresi A; Trojano M;
Ann Neurol; 2016 Jul; 80(1):89-100. PubMed ID: 27145331
[TBL] [Abstract][Full Text] [Related]
10. Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Gupta S; Zivadinov R; Ramanathan M; Weinstock-Guttman B
Expert Rev Neurother; 2016 Jul; 16(7):765-75. PubMed ID: 27138997
[TBL] [Abstract][Full Text] [Related]
11. Some recent advances in multiple sclerosis.
McCarthy C; Thorpe J
J Neurol; 2016 Sep; 263(9):1880-6. PubMed ID: 27113601
[TBL] [Abstract][Full Text] [Related]
12. Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
Gabr RE; Hasan KM; Haque ME; Nelson FM; Wolinsky JS; Narayana PA
J Magn Reson Imaging; 2016 Nov; 44(5):1293-1300. PubMed ID: 27126898
[TBL] [Abstract][Full Text] [Related]
13. Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
Davion JB; Cambron M; Duhin E; Chouraki A; Lacour A; Labauge P; Carra C; Ayrignac X; Vermersch P
J Neurol; 2016 Jul; 263(7):1361-3. PubMed ID: 27159986
[TBL] [Abstract][Full Text] [Related]
14. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
15. Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Habibi M; Kuttab HM
Am J Health Syst Pharm; 2016 Jun; 73(11):811-9. PubMed ID: 27126827
[TBL] [Abstract][Full Text] [Related]
16. Advanced MRI and staging of multiple sclerosis lesions.
Absinta M; Sati P; Reich DS
Nat Rev Neurol; 2016 Jun; 12(6):358-68. PubMed ID: 27125632
[TBL] [Abstract][Full Text] [Related]
17. Vision Disturbances in Multiple Sclerosis.
Costello F
Semin Neurol; 2016 Apr; 36(2):185-95. PubMed ID: 27116725
[TBL] [Abstract][Full Text] [Related]
18. Advanced Structural and Functional Brain MRI in Multiple Sclerosis.
Giorgio A; De Stefano N
Semin Neurol; 2016 Apr; 36(2):163-76. PubMed ID: 27116723
[TBL] [Abstract][Full Text] [Related]
19. Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.
Décard BF; Derfuss T
Semin Neurol; 2016 Apr; 36(2):128-39. PubMed ID: 27116719
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Ascherio A; Munger KL
Semin Neurol; 2016 Apr; 36(2):103-14. PubMed ID: 27116717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
